BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and...
BioCentury | Aug 18, 2020

Dragonfly’s TrinKET-enhancing cytokine platform sees early win with $475M BMS deal

Dragonfly has struck another deal with BMS for nearly half a billion dollars up front covering a clinical IL-12 program designed to complement its NK cell engager technology and other immunotherapies.  The biotech will receive...
BioCentury | Jul 23, 2020

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

BioNTech prices upsized financing BioNTech SE (NASDAQ:BNTX) raised $511.5 million in an upsized offering through the sale of 5.5 million ADSs at $93 per ADS. The deal, which had been slated for 5 million ADSs,...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

Flagship’s Repertoire aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with a cytokine-loaded T cell candidate for cancer. Repertoire Immune Medicines Inc. emerged in...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

Two senior executives at Biogen Inc. (NASDAQ:BIIB) have stepped down this past week: EVP of Corporate Development Daniel Karp and Anirvan Ghosh, SVP, head of research and early development. Ghosh will become CEO of cellular...
BioCentury | Mar 2, 2020

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

Xilio plans to bring its two lead immuno-oncology candidates to clinical proof-of-concept data, as well as advance its earlier stage programs, with a tranched $100.5 million series B. Takeda Ventures Inc. led the financing with...
BioCentury | Feb 8, 2020
Targets & Mechanisms

Astellas lays groundwork for oncolytic virus combination therapy

With its next-gen oncolytic virus, Astellas is reinforcing the promise of improved efficacy for versions that make cytokines stimulating T cells as well as innate immune cells. After more than two decades in development with...
BioCentury | Dec 19, 2019
Company News

Takeda adds oncolytic viruses to pipeline via Turnstone deal

Takeda has partnered with Turnstone to discover and develop immunotherapies using the biotech’s engineered vaccinia virus platform in a deal that gives the Japanese pharma its first oncolytic virus. Turnstone Biologics Inc. will receive upfront...
BioCentury | Dec 5, 2019
Tools & Techniques

Using exosomes to switch myeloid cells

Driven by the natural biology of exosomes, Codiak has moved beyond diagnostics and targeted cancer therapies to embrace myeloid switching as a strategy to treat cancer. The biotech presented preclinical data Nov. 18 at the...
BioCentury | Nov 15, 2019
Preclinical News

Nov. 14 Preclinical Quick Takes: Gut microbe-targeting phage for alcoholic liver disease; plus Cellectis, Biomica, University of Michigan and Rubius

Bacteriophages for alcoholic liver disease In a study described in Nature , University of California San Diego researchers identified a strain of gut microbiome member Enterococcus faecalis that expresses the exotoxin cytolysin as a target for...
Items per page:
1 - 10 of 567